A group of researchers at Harvard Medical School has developed a strongly cationic nanoparticle that physically absorbs proteins to form a new type of drug-carrier complex in aqueous solution.
Reckitt Benckiser’ opioid addiction drug Suboxone delivered by sublingual film has shown a 'surprising' level of resilience against generic competition, the firm says as it plans to spin-out its pharmaceutical business.
Hikma has bought defunct manufacturer Ben Venue and says it could reactivate the site in the long-term, despite the transfer of equipment across its sterile injectables network.
GlaxoSmithKline has issued upbeat guidance despite a 12% fall in sales of its blockbuster asthma and COPD drug Advair, as new products enter the respiratory drug market.
MonosolRx has found a new US licensee for its oral film ondansetron product, Zuplenz, signing up Galena BioPharma nearly four years after previous partner Strativa handed the drug back.
Drugmakers are bringing sterile injectables capacity back in-house according to a Frost & Sullivan analyst, who says industry risk aversion is the key driver.
Botox maker Allergan announced sales and earnings per share growth above the high end of its expectations, but it will cut 1,500 jobs, or about 13% of its workforce as it continues to avoid a $54bn hostile takeover bid from Valeant Pharmaceuticals.
Pfizer and Sun Pharmaceutical Industries have boosted their sterile injectables businesses through the respective acquisitions of InnoPharma and the CMO Pharmalucence.
Hovione has teamed up with delivery tech developer Merrion Pharmaceuticals to provide developers of BCS class III and IV drugs with more solubility enhancement options.
The US FDA approved Afrezza last weekend after deeming that the inhaled insulin drug and the dry powder delivery technology used to get it deep into the lungs is effective.
Oasmia Pharmaceutical AB has teamed up with a “global pharmaceutical company” interested in its vitamin A-based nanoparticle formulation tech in a move that expands its business model to drug development partnering.
Copley Scientific has launched new technologies to help developers of generic inhalable drugs stick to specific testing guidelines issued by the US FDA and USP.
Two billion cartridges of inhaled insulin drug Afrezza will be manufactured annually by Mannkind, the firm says as it awaits final approval next month.
A single-dose of an investigational MRSA drug could be equivalent to a ten-day course of antibiotics due to the application of PK-PD principles in its design and optimization, The Medicines Company says.
Capsugel has installed a commercial-scale dryer in its recently acquired Bend Research R&D facility, citing a rise in demand for non-GMP spray dried dispersion (SDD) services.
As part of a wave of good news for the beleaguered Hospira, the company said it will inject $120m into its McPherson, Kansas, facility, which will result in 150 new jobs over the next five years.
Researchers in Texas have unveiled the fastest, smallest motor to date, which could pave the way for similar motors moving through the body to administer drugs or to target cancer cells.
US scientists have tinkered with a virus so that it opens its cargo doors only in the presence of certain enzymes that could be used to drop therapeutics precisely onto a target.
A collaboration involving academia and industry is to develop new ways of delivering antibodies to the brain using molecular envelop technology developed by Nanomerics, a UCL spin-out company.
Chemists at MIT have created a triple warhead against cancer. They believe theirs is the first example a polymer nanoparticle which carries a precise ratio of three drugs that can be released in response to three distinct triggers.
Unilife says it is confident future revenue from current contracts could total $1bn and is scaling up manufacturing capacities despite no product sales in the third quarter.
Bayer says it will become the OTC leader in North America having acquired Merck & Co.’s consumer health business for $14.2bn (€10.2bn), in the latest shift in Big Pharma assets.
Capsugel is no longer a simple capsule provider but a differentiated player in the CDMO industry, the firm says as it wins a scale-up manufacturing contract for Chiasma and Roche’s oral octreotide candidate.
Researchers in Switzerland have devised a form of gold nanoparticle that shows promise as a weapon against tumours and as a delivery vehicle for drugs.
Endo Pharmaceuticals, which previously lost a bid to acquire a migraine treatment, has now acquired worldwide rights to Sumavel DosePro (sumatriptan injection) for subcutaneous use, which is a needle-free delivery system for Zogenix’s migraine treatment...
Opko Health has agreed to acquire Inspiro Medical, an Israeli medical device company developing a new platform to deliver small molecule drugs such as corticosteroids and beta agonists or larger molecules to treat respiratory diseases.
Novartis has agreed to acquire GlaxoSmithKline’s oncology pipeline for as much as $16bn, while GSK will acquire Novartis’ vaccine business, excluding the flu vaccines, for as much as $7bn.
RNA interference (RNAi) developers that saw stock prices fall after Novartis pulled out of the market last week have reiterated their belief in the therapeutic and revenue potential of gene silencing drugs.
Hovione has obtained a US patent for a cheap capsule-based dry powder inhaler that it claims is cheaper for manufacturers to produce and easier for patients to use.
Recent outbreaks of a strain of meningitis, known as “serogroup B” or “MenB”, on US college campuses have caused both Pfizer and Novartis to develop new vaccines.
Molecular Profiles has invested in hot melt extrusion (HME) and nano milling capabilities citing client demand for improving the bioavailablity of drugs.
A consortium developing treatments for children infected by parasitic worms has signed up Brazilian drugmaker Fiocruz as a formulation and manufacturing partner to support upcoming clinical trials.
A US FDA review panel has recommended that Afrezza be approved and concluded that the technology used to deliver MannKind's inhalable insulin does not damage airways or lung cells.
ADC-makers could avoid using costly cytotoxics in antibody-drug conjugates (ADCs) by using near‐infrared (NIR) light to activate targeted cell-killing payloads, says Goodwin who has team up with Aspyrian Therapeutics.
GSK has ‘smashed’ production targets at a UK inhaler plant by revving up manufacturing operations with knowhow developed in Formula One pit lanes by partner, McLaren.
The US FDA has published guidance of how sponsors should best document the bioavailability of products for investigational new drug applications (INDs) and new drug applications (NDAs).
Aegis Therapeutics claims a technology developed to improve the bioavailability of drugs delivered through the nose has a similar solubility enhancement effect in a solid dosage form.
Addiction doctors have petitioned the US FDA to prevent Zohydro ER, the first single-entity hydrocodone painkiller, hitting the market this month citing its potential for abuse. Its maker, Zogenix, has been tight-lipped on whether the drug’s formulation...
European regulators have been accused of making “no attempt” to counter misuse of prescription drugs in comparison with North American efforts to reformulate and restrict addictive drugs, according to a Canadian firm testing the abuse potential of medicines.
